Next-generation drug conjugates in the spotlight at AACR

Next-generation iterations of antibody-drug conjugate constructs are on display at this year’s AACR conference as companies and academic groups work to improve upon — and broaden the capabilities of — the modality’s first generation. 

BioCentury’s analysis of the abstracts released ahead of the American Association for Cancer Research (AACR) virtual meeting that runs from April 10-15 identifies a series of abstracts describing drug conjugate structures that may offer better tissue penetration and faster onset of action than traditional ADCs...